CD86 and Schwartz-Jampel syndrome: Similar to the results in HD PBMCs, KPL-404 alone did not increase the expression of cell activation markers CD69 and CD86 on CD19+ B cells from SjS or SLE patients (Fig. 6a–d and S6A-C).